Healthcare -
Drug Manufacturers - General - NYSE - UK
$ 37.17
-3.47 %
$ 75.6 B
Market Cap
18.47
P/E
1. INTRINSIC VALUE
Balance Sheet
GSK plc
| Current Assets | 17 B |
| Cash & Short-Term Investments | 3.71 B |
| Receivables | 6 B |
| Other Current Assets | 7.28 B |
| Non-Current Assets | 42.5 B |
| Long-Term Investments | 1.21 B |
| PP&E | 10.1 B |
| Other Non-Current Assets | 31.2 B |
| Current Liabilities | 21.7 B |
| Accounts Payable | 3.46 B |
| Short-Term Debt | 2.35 B |
| Other Current Liabilities | 15.9 B |
| Non-Current Liabilities | 24.7 B |
| Long-Term Debt | 14.6 B |
| Other Non-Current Liabilities | 10 B |
EFFICIENCY
Earnings Waterfall
GSK plc
| Revenue | 31.4 B |
| Cost Of Revenue | 9.05 B |
| Gross Profit | 22.3 B |
| Operating Expenses | 18.3 B |
| Operating Income | 4.02 B |
| Other Expenses | 1.07 B |
| Net Income | 2.95 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
GSK plc
| Net Income | 2.95 B |
| Depreciation & Amortization | 2.55 B |
| Capital Expenditures | -2.98 B |
| Stock-Based Compensation | 344 M |
| Change in Working Capital | 2.09 B |
| Others | 662 M |
| Free Cash Flow | 3.57 B |
Wall Street Analysts Price Targets
GSK plc
Wall Street analysts predict an average 1-year price target for GSK of $49.6 , with forecasts ranging from
a
low of
$35.2 to a high of $85 .
GSK Lowest Price Target
Wall Street Target
35.2 USD
-5.17%
GSK Average Price Target
Wall Street Target
49.6 USD
33.40%
GSK Highest Price Target
Wall Street Target
85 USD
128.68%
4. DIVIDEND
ANALYSIS
1.02%
DIVIDEND YIELD
0.422 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
GSK plc
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
5 Reasons GSK Looks Good
GSK's stock price has significantly outperformed the healthcare sector this year, supported by its healthy Q1 2025 numbers. Both turnover and EPS growth exceeded expectations, and the company's guidance indicates that the stock's forward P/E is competitive too. Additionally, GSK's medium-to-long-term financial prospects look good too, based on the company's latest outlook, which also works in the stock's favour.
seekingalpha.com
- 2 weeks ago
Here's Why GSK (GSK) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com
- 2 weeks ago
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance
GSK reports mixed first-quarter 2025 results. Shares rise in pre-market after it reaffirms guidance and says it is "well positioned" to handle the U.S. tariffs.
zacks.com
- 2 weeks ago
GSK plc (GSK) Q1 2025 Earnings Conference Call Transcript
GSK plc (NYSE:GSK ) Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ET Company Participants Constantin Fest - Head of IR Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Julie Brown - CFO David Redfern - President Corporate Development Tony Wood - Chief Scientific Officer Conference Call Participants James Gordon - JP Morgan Kerry Holford - Berenberg Jo Walton - UBS Graham Parry - Bank of America Simon Baker - Redburn Rajan Sharma - Goldman Sachs Sarita Kapila - Morgan Stanley Constantin Fest Ladies and gentlemen, a very warm welcome to this GSK Q1 2025 Results Call. My name is Constantin Fest, new head of IR at GSK, and I'm delighted to be joined today by Emma Walmsley, Luke Miels and Julie Brown.
seekingalpha.com
- 2 weeks ago
Here's Why GSK (GSK) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
- 2 weeks ago
Cervarix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts | GSK Leads Cervarix Market Amid Global Vaccination Efforts
The Cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. Key drivers include rising HPV awareness, vaccination rates, and global immunization programs. GSK plc leads the market, with Cervarix targeting HPV-linked conditions like cervical cancer. Advanced HPV vaccines and personalized immunization strategies are emerging trends. The report details market dynamics, historical data, and future growth projections. The Cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. Key drivers include rising HPV awareness, vaccination rates, and global immunization programs. GSK plc leads the market, with Cervarix targeting HPV-linked conditions like cervical cancer. Advanced HPV vaccines and personalized immunization strategies are emerging trends. The report details market dynamics, historical data, and future growth projections.
globenewswire.com
- 2 weeks ago
Britain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales
On Wednesday, British multinational pharmaceutical GSK Plc GSK reported first-quarter sales of $9.46 billion (7.52 billion Sterling Pounds), up 2% year-over-year and 4% on constant currency. Analysts had estimated sales of $7.46 billion.
benzinga.com
- 2 weeks ago
GSK Jumps On Solid Earnings, Says It's 'Well Positioned' To Navigate Tariffs
GSK stock jumped early Wednesday after the drugmaker reported adjusted earnings of $1.20 per share on $10.06 billion in first-quarter sales.
investors.com
- 2 weeks ago
GSK Posts Strong Results, Says 'Well Positioned' in Case of Pharma Tariffs
U.S.-listed shares of GSK (GSK) are gaining in premarket trading Wednesday after the British pharma giant posted better-than-expected first-quarter results and said it was "well positioned" should the Trump administration imposes tariffs against the industry.
investopedia.com
- 2 weeks ago
GSK: Disproportionately discounted, but earnings beat shows signs of reappraisal
Shore Capital is sticking with its upbeat view on GSK PLC (LSE:GSK, NYSE:GSK), calling the stock “disproportionately discounted” after first-quarter numbers surpassed expectations and guidance was held, despite headwinds from foreign exchange and political noise around drug pricing. The key beat came on earnings, with core EPS up 5% at constant exchange rates to 44.9p, a full 10% ahead of consensus.
proactiveinvestors.co.uk
- 2 weeks ago
GSK (GSK) Q1 Earnings Surpass Estimates
GSK (GSK) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.09 per share a year ago.
zacks.com
- 2 weeks ago
GSK jumps 4% as earnings beat boosts confidence
GSK PLC (LSE:GSK, NYSE:GSK) shares rose 4% on Tuesday, adding £2.6 billion to its market value, after the drugmaker delivered better-than-expected first-quarter results and reiterated full-year guidance. The FTSE 100 group reported core earnings per share of 44.9p, 10% ahead of consensus, thanks to stronger operating leverage and a robust margin of 33.7%.
proactiveinvestors.co.uk
- 2 weeks ago
8. Profile
Summary
GSK plc GSK
COUNTRY
UK
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 75.6 B
Dividend Yield
1.02%
Description
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
Contact
980 Great West Road, Brentford, TW8 9GS
https://www.gsk.com
IPO
Date
March 28, 1980
Employees
68629
Officers
Mr. Tony Wood
Chief Scientific Officer and Head of R&D
Mr. Philip C. Thomson
President of Global Affairs
Ms. Shobie Ramakrishnan
Chief Digital & Technology Officer
Ms. Diana Conrad
Chief People Officer
Ms. Julie Belita Brown A.C.A.
Chief Financial Officer & Executive Director
Ms. Sally Jackson
Senior Vice President of Global Communications & Chief Executive Officer Office
Mr. James Ford
Senior Vice President & Group General Counsel of Legal & Compliance
Ms. Emma Natasha Walmsley
Chief Executive Officer & Director
Mr. Luke V. Miels
Chief Commercial Officer
Mr. David Simon Redfern BSc (Hons), CA
President of Corporate Development